SQI Diagnostics Inc., a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced that effective August 27, 2021, it has granted an aggregate of 3,385,000 stock options to a consultant and certain employees and officers of the Company under the Company’s amended and restated stock option plan.
TORONTO, Aug. 30, 2021 /PRNewswire/ - SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective August 27, 2021, it has granted an aggregate of 3,385,000 stock options (“Options”) to a consultant and certain employees and officers of the Company under the Company’s amended and restated stock option plan (the “Plan”). The goal of the grant of Options is to align the interests of the Company’s employees, officers and directors with those of shareholders. The Options were granted at an exercise price of $0.175.
The Plan was approved by shareholders at the Company’s annual and special meeting held on March 31, 2021. The Options have a term of 5 years and vest over a maximum period of 36 months. Following the grant of Options, there will be 15,300,819 Options outstanding. There are currently 362,530,239 shares outstanding.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that is leading the way in healthcare utilizing state-of-the-art technology to rapidly diagnose, triage and provide medical insights to patients. We strive to improve people’s lives and assist their healthcare providers by providing quality clinical health information backed by years of research and clinical data. For more information, please visit www.sqidiagnostics.com.
Contact:
Chief Financial Officer
Morlan Reddock
416.674.9500 ext. 277
mreddock@sqidiagnostics.com
FORWARD-LOOKING INFORMATION
This press release contains certain words and statements, which may constitute “forward-looking statements” within the meaning of applicable securities laws relating to future events or future performance and reflect the current expectations and assumptions of the Company regarding its growth, results of operations, performance, business prospects and opportunities. These statements generally can be identified by use of forward-looking words such as “may”, “would”, “could”, “will”, “should”, “expect”, “plan”, “estimate”, “anticipate”, “intends”, “believe”, “potential”, or “continue” or the negative thereof or similar variations. The Company’s actual results and performance discussed herein could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, the effect of the global pandemic and consequent economic disruption, and the factors detailed in the Company’s ongoing filings with the securities regulatory authorities, available at www.sedar.com. Although the forward-looking statements contained herein are based on what we consider to be reasonable assumptions based on information currently available to us, there can be no assurance that actual events, performance or results will be consistent with these forward looking statements, and our assumptions may prove to be incorrect. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sqi-diagnostics-inc-announces-grant-of-stock-options-301365101.html
SOURCE SQI Diagnostics Inc.
Company Codes: OTC-PINK:SQIDF, OTC-QB:SQIDF, TorontoVE:SQD, OTC-BB:SQIDF
